Year: 2020

Continuing to Serve Customers In-Store and OnlineMAHWAH, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — ascena retail group, inc. (OTCMKTS: ASNAQ) and certain of its subsidiaries (collectively, “ascena” or the “Company”) today announced that it has completed the sale of the Ann Taylor, LOFT, Lou & Grey, and Lane Bryant brands to Premium Apparel LLC, an affiliate of Sycamore Partners. Premium Apparel has committed to retaining a substantial portion of the retail stores, associates, and corporate operations affiliated with these brands.“We are pleased to have completed this transaction, which secures a path for the long-term success of Ann Taylor, LOFT, Lou & Grey, and Lane Bryant,” said Gary Muto, Chief Executive Officer. “We have worked diligently to maximize the value of our brands, and we are confident they will thrive under...

CARROLLTON, Texas, Dec. 23, 2020 (GLOBE NEWSWIRE) — ADDvantage Technologies Group, Inc. (NASDAQ: AEY) (“ADDvantage Technologies” or the “Company”) today announced that Michael Burch has been promoted to Vice President of Network Solutions at Nave Communications.“This promotion recognizes the tremendous value Mike has added to our customers and Nave Communications over his 16-year tenure,” commented Reggie Jaramillo, President of the Telecommunications segment. “Mike has worked with our customers to develop network solutions and to provide equipment and services that enhance the customer experience. His knowledge of networks and creative thinking allow Mike to provide value adding and cost-effective solutions.”Mr. Burch began his career with Nave Communications in 2004 serving as an assistant to the VP of Sales. He subsequently learned...

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.10x Genomics’ management is scheduled to present on Monday, January 11 at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.comAbout 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products...

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.To access the webcast presentations, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology...

CALGARY, Alberta, Dec. 23, 2020 (GLOBE NEWSWIRE) — Gibson Energy Inc. announced today that it has completed the previously announced redemption of its outstanding 5.25% convertible unsecured debentures due July 15, 2021 (the “Debentures”).The redemption terms were in accordance with the provisions of the trust indenture governing the Debentures, and were as follows:The aggregate outstanding principal amount of the Debentures was $99.3 million on the date of Gibson’s redemption announcement on November 20, 2020. Pursuant to the conversion option available to holders of the Debentures, an aggregate of 134,916 common shares were issued in relation to conversion requests received by Gibson between the date of its redemption announcement and December 23, 2020. The remaining outstanding principal amount of Debentures was redeemed on the...

WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA). The NDA for VP-102 was resubmitted based on the outcome and final minutes of a Type A meeting with the FDA, which was conducted to obtain clarity on the Complete Response Letter (CRL) issued by the FDA in July 2020. “We are pleased that we were able to expeditiously provide a comprehensive resubmission of the NDA focused on the Chemistry, Manufacturing and Controls (CMC) information as well as Human Factors validation identified by the...

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — 9 Capital Corp. (the “Company”) announces that it has entered into a binding agreement dated December 23, 2020 (the “Letter Agreement”) with Churchill Diamond Corporation (“Churchill”), an arm’s length, Ontario based mineral exploration company which currently holds three mineral exploration projects in Canada, to effect a business combination of the two companies (the “Proposed Transaction”). The Proposed Transaction will be a reverse takeover of the Company by Churchill and its shareholders.Churchill is a private Ontario company managed by career mining industry professionals which currently holds three exploration projects, namely Taylor Brook in Newfoundland, Pelly Bay in Nunavut and White River in Ontario. All three projects are at the evaluation stage, with known mineralized Ni-Cu-Co...

LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) — At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would account for the recent increase in market activity.About AcastiAcasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe...

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — Shawcor Ltd. (“Shawcor” or the “Company”) (TSX: SCL) today announced the sale of its Pipeline Performance Products business (the “Products business”) to Seal For Life Industries (“Seal For Life”), a platform of Arsenal Capital Partners, a private equity investment firm based out of New York. The purchase price was USD $91.5 million, subject to working capital adjustments.“The Products business has provided stable returns to Shawcor for many years. However, most recently it has presented limited strategic alignment with Shawcor’s forward-looking direction, and the Company had the opportunity to obtain full value on disposition. Furthermore, the sale of the business allows the Company to focus on areas where it has the greatest differentiation opportunity for long term growth and serves to...